MAM
Global Communications Alliance: Markus Hilse from navos is newly elected chair
NEW DELHI: The Global Communications Alliance (GCA), a network of 15 independent communications agencies covering four continents and 21 countries, has announced that Markus Hilse, managing director of navos – Public Dialogue Consultants (Germany) has been newly elected as chair. Mavcomm Consulting Pvt Ltd is the only Indian member of the Global Communications Alliance.
"We look forward to taking the GCA to the next level. International know-how and transnational independent and innovative communication services are now more important than ever," Hilse said. An international change communications offering will be the next client service initiative of the GCA.
Hilse takes up the role in challenging times. Covid2019 is the single major challenge for all Corporate Communications and Public Affairs agencies within the GCA global network. As a result, participating in an ongoing exchange about strategy, staff engagement and new service-offerings in these tough times is a significant value-add for member agencies.
Mavcomm Consulting co-founder Anand Mahesh Talari said, “Hilse has played a rock-solid role in the development of GCA and I am confident that under Hilse’s leadership, GCA will play a key role for corporations around the world looking for the advantage of a global strategy with native specialists. I wish Hilse all the best for his role in the chair. We are looking forward to introducing to Indian transnational companies the international change communications offering of GCA.”
Hilse brings more than two decades of senior communications experience to the role. navos is a founding member of the Global Communications Alliance. Christian Simon, Senior Consultant and Head of International Affairs, will support Hilse in his work at navos and takes responsibility for enlarging the group further.
The GCA’s previous Chair was Susan Smith, Principal of Bluesky Strategy Group (Canada). During the last two years Smith professionalized the alliance, improving exchange between member agencies, and successfully enlarging the network. navos recently hosted the network’s 5th summit as a digital event and hopes to welcome all partners to Berlin for the GCA’s 6th global summit in spring 2021.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
